NeuroOne Medical Technologies Corporation (NMTC)

NasdaqCM

$1.03-5.50% today

Price as at 30 Sept 2026, 21:50 UTC. Quotes are delayed.

Fundamentals

52-week range$1.01 to $6.96

Valuation and ratings

NeuroOne Medical Technologies Corporation trades at $1.03. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.

About NeuroOne Medical Technologies Corporation

NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders. The company has a collaboration with the Department of Neurology's Division of Epilepsy at the University of Minnesota Medical School to advance a study evaluating epilepsy therapies. The company is based in Eden Prairie, Minnesota.

Industry: Medical DevicesEmployees: 18HQ: United States

Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.

Common questions

Where does SteadyShares get its NMTC data?

Fundamentals for NMTC come from company filings and exchange data, as listed on NasdaqCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 21:50 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.

The full research page for NMTC, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.

Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.